Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Juraska

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Biostatistics (Oxford, England)|June 22, 2025
A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine developmentPeter B Gilbert, James Peng, Larry Han, et al.
Plos One|June 17, 2020
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin AmericaLindsay N Carpp, Youyi Fong, Matthew Bonaparte, et al.
The American Journal of Tropical Medicine and Hygiene|May 23, 2019
Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody ResponsePeter B Gilbert, Ying Huang, Michal Juraska, et al.
JCI Insight|May 18, 2018
TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25Elizabeth A Thompson, Sebastian Ols, Kazutoyo Miura, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trialsMichal Juraska, Craig A Magaret, Jason Shao, et al.
Human Immunology|October 12, 2021
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in ThailandRasmi Thomas, Danaya Chansinghakul, Kriengsak Limkittikul, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participantsYunda Huang, Lily Zhang, Amanda Eaton, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
Plos Computational Biology|April 2, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence featuresCraig A Magaret, David C Benkeser, Brian D Williamson, et al.
Frontiers in Reproductive Health|June 25, 2025
Pregnancy and contraceptive use among participants of childbearing potential in the HVTN 705 HIV vaccine trial in Southern AfricaPamela Mda, Kathryn Mngadi, Bo Zhang, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Biostatistics (Oxford, England)|June 22, 2025
A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine developmentPeter B Gilbert, James Peng, Larry Han, et al.
Plos One|June 17, 2020
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin AmericaLindsay N Carpp, Youyi Fong, Matthew Bonaparte, et al.
The American Journal of Tropical Medicine and Hygiene|May 23, 2019
Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody ResponsePeter B Gilbert, Ying Huang, Michal Juraska, et al.
JCI Insight|May 18, 2018
TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25Elizabeth A Thompson, Sebastian Ols, Kazutoyo Miura, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trialsMichal Juraska, Craig A Magaret, Jason Shao, et al.
Human Immunology|October 12, 2021
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in ThailandRasmi Thomas, Danaya Chansinghakul, Kriengsak Limkittikul, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participantsYunda Huang, Lily Zhang, Amanda Eaton, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
Plos Computational Biology|April 2, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence featuresCraig A Magaret, David C Benkeser, Brian D Williamson, et al.
Frontiers in Reproductive Health|June 25, 2025
Pregnancy and contraceptive use among participants of childbearing potential in the HVTN 705 HIV vaccine trial in Southern AfricaPamela Mda, Kathryn Mngadi, Bo Zhang, et al.
Pageof 6